|
|
|
|
|
 |
|
 |
|
|
|
| |
|
| |
S3-1
2017 Taiwan Lipid Guidelines for High Risk Patients
李貽恆
成大醫院心臟內科
Yi-Heng Li, MD, PhD, FESC, FACC
Division of Cardiology
National Cheng Kung University Hospital & College of MedicineTainan, Taiwan
|
| Lipid control is important for patients with existed atherosclerotic cardiovascular diseases (ASCVD). The 2017 Taiwan Lipid Guidelines for High Risk Patients was published. The guidelines provide recommendations for adequate control of dyslipidemia for high risk patients. Lipid-lowering drugs include HMG-CoA reductase inhibitors (statins), cholesterol absorption inhibitors (ezetimibe), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, nicotinic acids (niacin), fibric acids derivatives (fibrates), and long-chain omega-3 fatty acids. Statin is usually the first line therapy. Combination therapy with statin and other lipid-lowering agents may be considered in some clinical settings. The talk will make a brief overview of the guideline. Especially, the pharmacological therapies for dyslipidemia in patients with ASCVD will be reviewed and focus on how to assist patients to reach the treatment target. |
|
|
|
|
| |
|
|
 |
|
